Fintel reports that on July 9, 2025, UBS downgraded their outlook for Thermo Fisher Scientific (NYSE:TMO) from Buy to Neutral.

Analyst Price Forecast Suggests 35.15% Upside

As of June 19, 2025, the average one-year price target for Thermo Fisher Scientific is $567.31/share. The forecasts range from a low of $454.50 to a high of $805.35. The average price target represents an increase of 35.15% from its latest reported closing price of $419.78 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Thermo Fisher Scientific is 48,792MM, an increase of 13.74%. The projected annual non-GAAP EPS is 28.08.

What is the Fund Sentiment?

There are 3,842 funds or institutions reporting positions in Thermo Fisher Scientific. This is an decrease of 72 owner(s) or 1.84% in the last quarter. Average portfolio weight of all funds dedicated to TMO is 0.59%, an increase of 3.12%. Total shares owned by institutions decreased in the last three months by 2.51% to 384,463K shares. The put/call ratio of TMO is 0.86, indicating a bullish outlook.

What are Other Shareholders Doing?

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 11,913K shares representing 3.16% ownership of the company. In its prior filing, the firm reported owning 11,982K shares , representing a decrease of 0.58%. The firm decreased its portfolio allocation in TMO by 0.79% over the last quarter.

Capital World Investors holds 11,061K shares representing 2.93% ownership of the company. In its prior filing, the firm reported owning 9,430K shares , representing an increase of 14.75%. The firm increased its portfolio allocation in TMO by 19.74% over the last quarter.

VFINX - Vanguard 500 Index Fund Investor Shares holds 10,627K shares representing 2.82% ownership of the company. In its prior filing, the firm reported owning 10,354K shares , representing an increase of 2.58%. The firm increased its portfolio allocation in TMO by 0.25% over the last quarter.

Jpmorgan Chase holds 10,138K shares representing 2.69% ownership of the company. In its prior filing, the firm reported owning 8,918K shares , representing an increase of 12.03%. The firm increased its portfolio allocation in TMO by 6.63% over the last quarter.

Price T Rowe Associates holds 9,305K shares representing 2.46% ownership of the company. In its prior filing, the firm reported owning 10,917K shares , representing a decrease of 17.32%. The firm decreased its portfolio allocation in TMO by 12.86% over the last quarter.

Thermo Fisher Scientific Background Information
(This description is provided by the company.)

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.